Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced findings from its IMPACT-TD Registry showing that only 23% of young adults aged 18-29 with mood disorders and tardive dyskinesia symptoms received a formal TD diagnosis, despite 85% experiencing moderate to severe impact from the condition.

The data, presented at the 2026 American Psychiatric Association Annual Meeting in San Francisco, analyzed 211 adults with TD who had concomitant mood disorders including bipolar disorder (60%) and depression (54%). The IMPACT-TD Registry is described as the largest TD study to date, examining 611 participants aged 18 and older.

The study found that formal TD diagnosis rates were lowest among adults under 40 years old, with 23% for those aged 18-29 and 35% for those aged 30-39, compared to 57% for adults aged 40-49. Patients experienced an average delay of more than 3.5 years between first recognition of involuntary movements and formal diagnosis.

The psychological impact was most pronounced in adults under 60, with 77% of those aged 18-29 experiencing moderate to severe psychological effects despite having lower average AIMS scores (6.4) compared to older adults aged 60-69 (8.4) and over 69 (9.9).

Tardive dyskinesia is a movement disorder characterized by uncontrollable, abnormal movements that affects approximately one in four people taking certain mental health treatments. The IMPACT-TD Registry is a three-year, prospective study examining how TD progresses over time and its impact on patients' lives.

The findings were based on a company press release statement.